Background/Aims: Chronic kidney disease (CKD) is one of the major complications of hypertension. It is not only associated with the future burden of end-stage renal disease but also affects mortality and cardiovascular outcomes caused by hypertension. To help understand the pathogenesis and early prevention of progressive CKD, this large-scale study is designed to determine the complex association between serum uric acid (SUA), metabolic syndrome and the prevalence of CKD in hypertensive patients. Methods: A total of 19,848 hypertensive subjects were enrolled in this cross-sectional study. Patients with proteinuria and/or an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m 2 were considered CKD cases. Results: Hypertensive subjects with CKD had a higher prevalence of hyperuricemia and metabolic syndrome, as well as higher levels of SUA, BMI, waist circumference (WC), SBP, DBP, TG, fasting blood glucose and lower levels of HDL-C. Compared to patients without CKD, the multivariate-adjusted odds ratios [ORs, 95% confidence interval (CI)] for CKD patients were 2.30 (2.02-2.63) for hyperuricemia, 1.21 (1.04-1.41) for abdominal obesity, 1.21 (1.06-1.38) for elevated TG, 1.29 (1.06-1.56) for low HDL-C, 1.54 (1.36-1.75) for elevated fasting glucose, and 1.49 (1.30-1.71) for metabolic syndrome. Increasing SUA levels and number of individual metabolic syndrome components were associated with an increased prevalence of CKD. Compared with patients classified in the lowest SUA categories and with ≤1 metabolic syndrome components, subjects with HUA and 4 metabolic syndrome components had a 5.77-fold increased OR for CKD based on the multivariate-adjusted analysis. Conclusion: Both elevated SUA and metabolic syndrome are associated with an increased prevalence of CKD in
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Introduction
Hypertension is one of the most costly and burdensome chronic diseases of our time and is a condition that is increasing rapidly throughout the world [1] . The complications resulting from hypertension are associated with the damage or failure of various organs, leading to significant morbidity and mortality [2] . CKD is one of the major complications associated with hypertension. Over the past decades, it has become increasingly evident that the prognosis, especially in terms of mortality and cardiovascular events, of hypertensive patients is strongly affected by renal involvement [3] . Therefore, the early detection and prevention of progressive CKD may not only alleviate the future burden of end-stage renal disease but also reduce the cardiovascular outcomes associated with hypertension [3] .
However, the complex pathogenesis of CKD has yet to be fully elucidated. Apart from hypertension and diabetes, metabolic syndrome was recently found to be significantly associated with CKD in some studies [4] [5] [6] [7] [8] [9] . Metabolic syndrome is a cluster of metabolic disorders, including abdominal obesity, elevated blood pressure, glucose intolerance, and dyslipidemia [10] . In hypertensive patients, the prevalence of metabolic syndrome is dramatically high and exhibits a remarkably increasing trend [11] . Thus, the role of metabolic syndrome in CKD deserves more attention in hypertensive patients.
Hyperuricemia (HUA), the precursor to gout, has also been suggested be a useful predictor of cardiovascular diseases such as CKD [12] [13] [14] . Many studies have reported an association between elevated SUA and CKD, whereby elevated SUA plays a causal role in the pathophysiology of CKD rather than occurring as a consequence of CKD [15, 16] . However, these results were mainly observed in the general population. Epidemiological evidence of this relationship in hypertensive patients is still limited. Moreover, reports on the association between elevated SUA and CKD that also take into account the number of metabolic syndrome risk factors have also been scant.
The present study is designed to determine whether elevated SUA, or even SUA levels in the normal range, and metabolic syndrome are associated with an increased prevalence of CKD in hypertensive patients. Moreover, the study also explores the combined association of SUA and metabolic syndrome on CKD to suggest whether the interaction of SUA and metabolic syndrome may affect the likelihood of CKD in hypertensive patients.
Materials and Methods

Study Subjects
The Health Management Center of the Third Xiang-Ya Hospital is one of China's largest examination centers, serving a population of more than 100,000 every year. In this cross-sectional study, we consecutively recruited 24,236 Chinese people from the center between March 2012 and December 2014. Inclusion criteria included age between 45 and 74 years and a diagnosis of hypertension according to the Seventh Joint National Committee (JNC-7) criteria [17] . Exclusion criteria included the following: 1) no available data on body weight, height, waist circumference (WC), blood pressure, fasting blood glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), SUA, serum creatinine (Scr), or urine analysis; 2) taking uric acid-lowering drugs; 3) a history of primary renal diseases; 4) renal artery stenosis; and 5) duplicate cases. In total, 19,848 hypertensive subjects, aged 45-74 years old, were finally screened and deemed eligible for this study. General characteristics of kept and excluded study subjects were shown in Table 1 .
The study was approved by the Medical Ethics Committee of the Third Xiang-Ya Hospital. All the subjects enrolled in this study provided informed consent to participate.
hypertensive subjects. Subjects with higher SUA and sum of individual metabolic syndrome components simultaneously have a higher prevalence of CKD.
Blood pressure was measured with an appropriately sized cuff and a mercury-column sphygmomanometer in the sitting position after a 10-min rest period. Height and body weight were measured with the subjects wearing lightweight clothing, and body mass index (BMI) was calculated as body weight divided by height squared. WC was measured at navel level in a standing position with light expiration. Venous blood sampling was performed after overnight fasting, and blood glucose, TC, TG, HDL-C, LDL-C, SUA, and Scr levels were determined using standard laboratory methods. Qualitative analysis of urinary protein was performed using the urine dipstick method, and the results were recorded as (-), (±), (1+), (2+), and (3+). The Glomerular filtration rate (GFR) was estimated using the equation of chronic kidney disease epidemiology collaboration (CKD-EPI). The GFR CKD-EPI was calculated as recommended: for women with Scr ≤0. 
×0.993
age [18] .
Definitions of Hyperuricemia, Metabolic Syndrome, and Chronic Kidney Disease
HUA was defined by an SUA level >7.0 mg/dl (416 μmol/L) for males and >6.0 mg/dl (357 μmol/L) for female [19] . Apart from the HUA group, normouricemic subjects were categorized into three groups for analysis according to the SUA tertiles as follows: T1 (≤5.04 mg/dL in men, ≤ 3.70 mg/dL in women), T2 (5.04-5.92 mg/dL in men, 3.70-4.54 mg/dL in women), and T3 (>5.92 mg/dL in men, >4.54 mg/dL in women).
Because all the patients had hypertension based on JNC-7 criteria, metabolic syndrome was defined as the presence of two or more of the following components: a WC of at least 90 cm in men and at least 80 cm in women; TG levels of at least 1.7 mmol/l; HDL-C <1.03 mmol/l in men and below 1.30 mmol/l in women; and fasting blood glucose ≥5.6 mmol/l or undergoing treatment for elevated glucose [10] . one cigarette/day), former (having quit for at least 6 months), or never smoking. For the analyses, only two categories were considered: current smoking (daily and occasional smoking) and non-smoking (never and former smoking). Alcohol consumption was recorded as current (at least once per week) or never.
Proteinuria was defined as dipstick proteinuria (≥1+) [20, 21] , and low eGFR was defined as eGFR <60 mL/min/1.73 m 2 . CKD was diagnosed based on the presence of proteinuria and/or a low eGFR in a single test [20, 21] .
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics Ver. 22.0. Data were expressed as the mean ± standard deviation (SD) for continuous variables and as numbers (percentages) for categorical variables. Comparisons of baseline characteristics by CKD status (with/without) were assessed using Student's t-tests and chi-square tests for continuous and categorical variables, respectively. The adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated to estimate the individual/combined SUA categories and metabolic syndrome components by logistic regression analyses. A P value of <0.05 was regarded as statistically significant.
Results
Characteristics of Study Subjects
The characteristics of all study subjects are presented in Table 2 . A total of 19,848 subjects with hypertension, 70.9% of whom were male (mean age: 57.8 ± 8.3 years), were included in this study. The prevalence of HUA, metabolic syndrome, and CKD in this hypertensive population were 17.2%, 50.6%, and 9.0%, respectively. When compared to those without HUA, the OR was 3.48 (95% CI, 2.89-4.19) for CKD after controlling for multiple confounding factors (Model 3). Among normouricemic subjects, patients in the T3 and T2 groups also had a higher prevalence of CKD than the T1 group (T3: OR 1.99, 95% CI, 1.66-2.39; T2: OR 1.46, 95% CI, 1.21-1.76; Model 3).
Association between Metabolic Syndrome, the Number of Metabolic Syndrome Components, and Chronic Kidney Disease
In models adjusted for age and sex, subjects with metabolic syndrome had 2.16-fold higher ORs of having CKD than those without. After further adjusting for various confounding factors (Table 3 , Model 3), subjects with metabolic syndrome had 1.49-fold higher ORs of having CKD than those without (P<0.001). Moreover, the ORs for CKD increased with increasing number of metabolic syndrome (all P<0.001 in models 1, 2, and 3; Table 4 ). Subjects with 2, 3, and 4 components of metabolic syndrome had increased ORs (95% CI) of 1.31 (1.12-1.52), 1.91 (1.60-2.27), and 2.08 (1.53-2.83), respectively, for CKD compared with the ORs of those with ≤1 components.
Combined Association of Serum Uric Acid and Metabolic Syndrome Components with Chronic Kidney Disease
Finally, the combined association of SUA and metabolic syndrome components on the prevalence of CKD were estimated after adjusting for age, sex, BMI, current smoking and drinking status, use of antihypertensive drugs, antidiabetic and hypolipidemic drugs, SBP, DBP, TC, and LDL-C (Table 5) . A formal test for interaction between SUA and metabolic syndrome components revealed a significant interaction (P<0.001). In the age-and sexadjusted model, subjects with HUA and 4 metabolic syndrome components had a 9.88-fold higher ORs of having CKD than those in the T1 group with ≤1 metabolic syndrome component. After further adjusting for other confounding factors, the ORs of CKD remained 5.77-fold greater in subjects with HUA and 4 metabolic syndrome components than in the T1 group with ≤1 metabolic syndrome components. As shown in Table 6 , similar results were also found by testing the combined association in a population with a more stringent cutoff of proteinuria (2+ or 3+).
Discussion
In this hypertensive population, the prevalence of HUA, metabolic syndrome, and CKD were 17.2%, 50.6%, and 9.0%, respectively. Both elevated SUA and an increased number of metabolic syndrome components were independently associated with a higher prevalence of CKD. Moreover, there was an interaction between SUA and metabolic syndrome components. Subjects with simultaneously higher SUA and a higher number of metabolic syndrome components were more likely to have CKD.
Serum Uric Acid and Chronic Kidney Disease
Uric acid has historically been recognized as a consequence of CKD. However, recent studies have suggested that uric acid itself may play a causal role in the development of CKD. According to a 4-year follow up of 41,632 males, HUA was identified as an independent risk factor for the development of kidney impairment [22] . In a meta-analysis of 15 cohort studies, each 1 mg/dL SUA increment was found to be significantly associated with a 1.22-fold CKD risk in middle-aged participants [23] . Nevertheless, these results were mainly found in the general population and rarely reported in hypertensive subjects. Hypertensive subjects usually suffer accompanying HUA and cardiovascular complications [24] . Our results demonstrated a significant association between SUA and CKD in hypertensive subjects on a large scale, even in the second and third tertiles of normal SUA.
Although the association between SUA and CKD has been explored for a long time, the underlying mechanism is still not completely understood. It has been suggested that SUA induced oxidative stress and endothelial dysfunction may result in the development of both systemic and glomerular hypertension, which would reduce renal blood flow and elevate renal vascular resistance [25, 26] . Uedono et al. [27] also found that SUA levels was significantly and independently associated with the vascular resistance at the afferent arteriole. In addition, SUA may stimulate vascular smooth muscle cell proliferation through the activation of the renin-angiotensin system [28] . Lowering uric acid in mice with allopurinol was able to improve the proinflammatory effects by reducing ICAM-1 expression in tubular epithelial cells [29] . Moreover, SUA was also able to induce an epithelial-to-mesenchymal transition, with direct effects on the renal tubular cells [30] . However, elucidating the complex mechanisms between SUA and CKD still requires further research.
Metabolic Syndrome and Chronic Kidney Disease
In recent years, an increasing number of studies has explored the association between metabolic syndrome, its components, and CKD. According to a cross-sectional study involving 15,987 individuals, metabolic syndrome was found to be significantly associated with the prevalence of CKD [4] . Kang et al. [5] also demonstrated a 1.53-fold increased ORs for CKD in Koreans with metabolic syndrome based on the general health screening data of 10,253,085 participants. Consistent with these findings, the positive effects of metabolic syndrome on the prevalence of CKD were shown in several studies [6] [7] [8] 31] . In the present study, we showed that metabolic syndrome was significantly associated with a 1.49-fold increased OR for CKD. This result agrees with previous studies, although these studies were performed in different groups in a variety of areas and sample sizes.
Our study also showed that every metabolic syndrome component was associated with an increased CKD risk. The strength of association between metabolic syndrome and the development of CKD increased progressively as the number of components increased from ≤1 to 4. This result was similar to those in previous reports by Song et al. [31] and Kang et al. [5] However, no positive association between elevated plasma glucose, elevated WC, and CKD was shown in a cross-sectional study of 6,217 U.S. adults [32] . In another study, elevated TG and obesity were regarded as noncritical components of metabolic syndrome [31] . The multivariate-adjusted ORs of decreased GFR were not significant for those with 1 or 2 noncritical components (versus zero components). Thus, the question of the association between individual components of metabolic syndrome and CKD remains controversial. Future studies should focus on identifying the dynamic response of the elements of metabolic syndrome to facilitate better intervention strategies.
Combined Association of Serum Uric Acid and Metabolic Syndrome Components with Chronic Kidney Disease
To the best of our knowledge, this work about the interactions of SUA and metabolic syndrome components change the ORs of CKD, in particular in hypertensive patients, for the first time. The present study also adds to the debate regarding whether increased SUA may be considered an additional independent component of metabolic syndrome just as abdominal obesity, glucose intolerance, and dyslipidemia [33] . However, the limitations of both the types of subjects and the cross-sectional design of the present study reduced the significance of our results. Further longitudinal cohort studies that include a variety of groups are needed to settle the debate. Moreover, further study should also ascertain whether the alteration of SUA and metabolic syndrome could prevent or delay the development of CKD in hypertensive subjects.
Our study also has some limitations. The primary limitation of this study is that crosssectional data do not allow us to observe the impact of risk factors over time and distinguish between reason and consequence. Another limitation is that proteinuria was only measured by dipstick, which is not sufficient for diagnosing CKD. A quantitative measurement of proteinuria is needed in further studies. In addition, the information on some associated variables such as smoking, drinking habits, renal artery measurements, and so on was prone to underreporting or lacking. Finally, our study has a huge overhang of male participants, which may cause biased outcomes. Given those limitations, further longitudinal cohort studies are needed to observe and analyze the causative relationship of SUA and metabolic syndrome with CKD in the hypertensive patients.
Conclusion
In summary, both elevated SUA and metabolic syndrome appear to be associated with an increased prevalence of CKD in hypertensive subjects. Subjects with higher SUA and sum of individual metabolic syndrome components simultaneously have a higher prevalence of CKD. Elevated SUA and metabolic syndrome should therefore be kept in mind as treatment targets in addition to obvious hypertension targets.
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